is compounded semaglutide being banned FDA moving to restrict mass-marketed GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified π¨ MASSIVE BREAKING: Compounded Semaglutide
Description
Post-marketing safety data and observational reports indicate mood changes occur in a subset of users, warranting individualized assessment before and during therapy
Refund difficulties appear in multiple negative reviews
However, semaglutide administration was associated with a marginal increase in central retinal thickness
Retatrutide is an investigational triple agonist peptide currently under clinical development, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously
